SCOTUS justices hint at uncertain future of Chevron doctrine in tangential case
Two looming decisions at the Supreme Court — one on the FDA’s regulation of a commonly used abortion drug and another on the fate of the Chevron doctrine — will have broad implications for not only the FDA but the entire biopharma industry too.
Oral arguments before the court on Tuesday also highlighted the likelihood that the Chevron doctrine could be overturned as part of a case on a North Dakota truck stop that became a party in litigation alleging that a 2011 cap on debit card fees unfairly favors banks. The truck stop is arguing that it deserves the chance to litigate the rule, even though the business wasn’t established until 2018, at which point the statute of limitations on the federal rule had expired.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
